In December 2024, Checkpoint announced that the U.S. Food and Drug Administration (“FDA”) approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback